PMA summary data release may be streamlined by FDA.
This article was originally published in The Gray Sheet
Executive Summary
SIMPLIFIED PMA DATA SUMMARY RELEASE UNDER CONSIDERATION BY FDA in an effort to reduce delays in making available to the public summaries of safety and effectiveness data on premarket approval applications, FDA staffers say. The initiative to streamline the process is in its early stages, according to FDAers.